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Background: Guizhi Fuling Formula is widely applied for uterine fibroids in China. Many clinical trials are reported.
This study assessed the efficacy and safety of Guizhi Fuling Formula for the treatment of uterine fibroids.
Methods: PubMed, Cochrane CENTRAL, EMBASE, and four Chinese databases were searched through May 2013. We
included randomised controlled trials (RCTs) that tested Guizhi Fuling Formula for uterine fibroids, compared with
no intervention, placebo, pharmaceutical medication, or other Chinese patent medicines approved by the State
Food and Drug Administration of China. Authors extracted data and assessed the quality independently. We
applied RevMan 5.2.0 software to analyse data of included randomised trials.
Results: A total of 38 RCTs involving 3816 participants were identified. The methodological quality of the included
trials was generally poor. Meta-analyses demonstrated that Guizhi Fuling Formula plus mifepristone were more
effective than mifepristone alone in reducing the volume of fibroids (in total volume of multiple fibroids,
MD −19.41 cm3, 95% CI −28.68 to −10.14; in average volume of multiple fibroids, MD −1.00 cm3, 95% CI −1.23
to −0.76; in average volume of maximum fibroids, MD −3.35 cm3, 95% CI −4.84 to −1.87, I2 = 93%, random effects
model). Guizhi Fuling Formula significantly improved symptoms of dysmenorrhea either when it was used alone
(RR 2.27, 95% CI 1.04 to 4.97) or in combination with mifepristone (RR 2.35, 95% CI 1.15 to 4.82). No serious adverse
events were reported.
Conclusions: Guizhi Fuling Formula appears to have additional benefit based on mifepristone treatment in
reducing volume of fibroids. However, due to high risk of bias of the trials, we could not draw confirmative
conclusions on its benefit. Future clinical trials should be well-designed and avoid the issues that are identified in
this study.
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Randomised clinical trialsBackground
Uterine fibroids are the most common benign tumor of
the female reproductive tract and occur in about 25% of
all women of reproductive age [1] and up to 30–40% of
women over age 40 [2]. It is estimated that 50% of fibroids
are asymptomatic [3]. When fibroids are symptomatic,
they present in a variety of ways such as menstrual prob-
lems, pain, pressure symptoms, and infertility. Current* Correspondence: jianping_l@hotmail.com
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stated.treatments include surgical approaches such as hysterec-
tomy, myomectomy, uterine artery embolization (UAE)
and magnetic resonance imaging–guided focused ultra-
sound surgery (MRgFUS), pharmacologic options such as
hormonal therapies and gonadotropin-releasing hormone
(GnRH) agonists [4]. However, surgery is associated with
operative mortality and morbidity [1]. Medical therapy is
similarly limited. GnRH agonists can relieve both bleeding
and bulk-related symptoms but might cause significant
menopausal side effects [5,6]. Progesterone antagonists,
such as mifepristone and asoprisnil, seem to be effective in
inducing fibroid regression without major adverse events.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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therapies that alter oestrogen and progesterone produc-
tion or function may affect fertility [7]. So safer therapy is
needed for uterine fibroids.
In China, traditional Chinese herbal medicine is a
prevalent treatment for uterine fibroids. Guizhi Fuling
Formula is one such common remedy. The formula was
first described in Essential Prescriptions from the Golden
Cabinet (Jingui Yaolue) by a famous Chinese doctor
Zhang Zhongjing of the Han Dynasty (third century A.
D.). Guizhi Fuling Formula consists of five herbs: Ramu-
lus Cinnamomi, Poria, Semen Persicae, Radix Paeoniae
Rubra or Radix Paeoniae Alba, and Cortex Moutan [8].
Its traditional effects (actions) are invigorating blood,
dissolving stasis, and resolving masses [9]. Common
preparations of the formula are pills, capsules, tablets,
and decoctions. A bibliometrics study of modern litera-
ture analysing the names of diseases that are treated by
Guizhi Fuling pills revealed that the highest frequency of
traditional Chinese medicine (TCM) diseases was ab-
dominal mass (zheng jia) and the highest frequency of
western medicine diseases was uterine fibroids [10].
A Cochrane systematic review [11] assessing herbal
preparations for uterine fibroids included ten clinical trials
of Guizhi Fuling Formula. Results showed that the com-
bination of Guizhi Fuling Formula and mifepristone was
associated with a greater reduction in fibroid volume and
in uterine size compared with mifepristone alone. In order
to assess the efficacy and safety of Guizhi Fuling Formula
for uterine fibroids, we conducted this study by compre-
hensively collecting and analysing randomised controlled
trials (RCTs) on Guizhi Fuling Formula.
Methods
The protocol of this systematic review was registered
in the PROSPERO database (http://www.crd.york.ac.uk/
PROSPERO/display_record.asp?ID=CRD42013003541).
Search strategy
We searched three English electronic databases and four
Chinese electronic databases from their inception through
May 2013: PubMed, Cochrane CENTRAL, EMBASE,
China National Knowledge Infrastructure (CNKI), Chinese
Biomedicine (SinoMed), Chinese Scientific Journals Data-
base (VIP), and WanFang Database. Conference proceed-
ings and dissertations were also searched from CNKI and
Wanfang databases for unpublished trials. The following
search terms (or the Chinese equivalent for Chinese data-
bases) were used individually or cross-linked and varied
depending on which database was searched: “leiomyoma”,
“leiomyomata”, “leiomyomas”, “fibroid”, “fibroids”, “uterine
myoma”, “uterine myomas”, “uterine fibroid”, ‘uterine
fibroids”, “uterine fibroma”, “uterine fibromas”, “Guizhi
Fuling Formula”, “Guizhi Fuling decoction”, “Guizhi Fulingtang”, “Guizhi Fuling capsules”, “Guizhi Fuling pills”,
“Guizhi Fuling tablets”, and “random”.
The specific search strategy of PubMed was as follows:
#1 Search ((((((((((leiomyoma[Title/Abstract]) OR
leiomyomata[Title/Abstract]) OR leiomyomas[Title/
Abstract]) OR fibroids[Title/Abstract]) OR fibroid
[Title/Abstract]) OR uterine myoma[Title/Abstract])
OR uterine myomas[Title/Abstract]) OR uterine
fibroids[Title/Abstract]) OR uterine fibroid[Title/
Abstract]) OR uterine fibroma[Title/Abstract]) OR
uterine fibromas[Title/Abstract]
#2 Search (((((guizhi fuling formula[Title/Abstract]) OR
guizhi fuling decoction[Title/Abstract]) OR guizhi
fuling tang[Title/Abstract]) OR guizhi fuling capsules
[Title/Abstract]) OR guizhi fuling pills[Title/Abstract])
OR guizhi fuling tablets[Title/Abstract]
#3 Search random
#1 and #2 and #3
Inclusion/exclusion criteria
Types of studies
We included randomised clinical trials (RCTs) assessing
the beneficial effect and safety of Guizhi Fuling Formula
for treating uterine fibroids. No language restriction was
applied.
Types of participants
We did not limit the diagnostic criteria, but comprehen-
sive criteria were accepted in terms of clinical symptoms,
signs, plus confirmation by ultrasonography.
Types of interventions
Guizhi Fuling Formula in any preparations such as pills,
capsules, decoctions, and tablets, orally taken, for the
treatment of uterine fibroids were included. The treatment
duration was no less than 30 days. Modified Guizhi Fuling
Formula prescribed according to TCM syndrome differen-
tiation was acceptable, and was defined by practitioners as
adding no more than five herbs to the five original herbs,
resulting in nearly the same actions as the original Guizhi
Fuling Formula. The controls could be no intervention,
placebo, medication, or other Chinese patent medicines
approved by the State Food and Drug Administration of
China. Trials testing combination of Guizhi Fuling For-
mula and medication compared with the same medication
were also included.
Types of outcome measures
Primary outcomes were volume of uterine fibroids and
symptom improvement: menstrual problems (extended,
more frequent, heavy menstrual bleeding, vaginal bleeding
at times other than menstruation, and anemia), abdominal
mass, pressure symptoms (difficulty urinating or frequent
Chen et al. BMC Complementary and Alternative Medicine 2014, 14:2 Page 3 of 10
http://www.biomedcentral.com/1472-6882/14/2urination, constipation), pain, leukorrhagia, infertility. Sec-
ondary outcomes were volume of uterus, recurrence rate,
quality of life (QOL), and adverse events.
Redundant published trials, poor data authenticity tri-
als (suspected fraud or plagiarism and information that
could not be confirmed by authors when contacted), and
trials with missing data not available from contacting the
authors were excluded.
Study selection and data extraction
Two authors (NNC, MH) conducted study selection and
data extraction independently. Extracted information in-
cluded: population, age and baseline characteristics; details
of the intervention and control conditions; follow up time
and outcome measures. Any disagreements were resolved
through discussion with a third author (JPL).
Assessment of risk of bias
Two authors (NNC, MH) independently assessed the
quality of included trials using the Cochrane risk of bias
tool [12]. The following items were assessed: random se-
quence generation, allocation concealment, blinding, in-
complete outcome data, selective outcome reporting, and
other bias. Sample size estimate, comparable baseline
characteristic, inclusion and exclusion criteria were con-
sidered when we judged the other bias. Disagreements
were resolved by discussion with a third author (JPL).
Data analysis
We applied RevMan 5.2.0 software to conduct data ana-
lyses. We used risk ratios (RR) with 95% confidence inter-
vals (CI) for binary outcomes or mean difference (MD)
with 95% CI for continuous outcomes. When different
measurement scales were used, standardised mean differ-
ence (SMD) analyses were performed. For cross-over tri-
als, only the first phase outcome data were analysed. We
applied fixed-effect model unless there was evidence of
heterogeneity. Heterogeneity was assessed using both the
Chi-squared test and the I-squared statistic with an I-
squared value greater than 50% indicative of substantial
heterogeneity. Funnel plots were generated to detect pub-
lication bias when more than ten trials were identified.
When the necessary data were available, subgroup analysis
was done for different parameters representing the volume
of fibroids.
Results
Study search and selection
We identified a total of 537 citations electronically, and
we included 38 trials at last (Figure 1).
Description of studies
Additional file 1 summarizes the characteristics of 38 in-
cluded trials involving 3816 participants. All includedtrials were conducted in China and published in Chinese.
Sample sizes varied from 39 to 195 participants, with an
average of 100.42 participants per trial. All participants
were diagnosed by clinical manifestation and ultrasonog-
raphy. There was only one multicentre trial [13]. All of the
trials had two arms, except two trials [14,15] that had
three arms.
There were six trials comparing Guizhi Fuling Formula
with western (conventional pharmaceutical) medicine; 30
trials comparing Guizhi Fuling Formula plus western
medicine with western medicine; and three trials compar-
ing Guizhi Fuling Formula with other Chinese patent
medicines. One of the two trials [14,15] with three arms
had two comparisons, which we counted twice. No trial
applied placebo or no intervention as control. Prepara-
tions of Guizhi Fuling Formula were capsules or pills in all
the included trials and were patent medicines approved by
the State Food and Drug Administration of China.
For outcome measures, 34 trials reported fibroid vol-
ume and 12 trials reported uterus volume, and the vol-
ume was measured by ultrasonography. Five trials
reported improvement of fibroid-related symptoms such
as heavy menstrual bleeding, prolonged menstrual bleed-
ing, vaginal bleeding at times other than menstruation,
distention pain of the lower back and abdomen, and dys-
menorrhea. Fifteen trials reported adverse events. Three
trials though reported recurrence rate, but they did not
define recurrence. No trial reported quality of life.
Of the 34 trials which reported fibroid volume, 21 trials
reported different parameters to represent the volume of
uterine fibroids. Among the 21 trials, 13 trials reported
average volume of maximum fibroids, two trials reported
total volume of multiple fibroids, four trials reported aver-
age volume of multiple fibroids, and two trials reported
average diameter of fibroids. For example, a woman has
three fibroids that are each 3 cm3, 4 cm3, and 11 cm3. If
the volume of the largest fibroid is measured, the reported
volume is 11 cm3; if total volume of multiple fibroids is
measured, it is 18 cm3; if average volume of multiple fi-
broids is measured, it is 6 cm3. To confirm the parameters
representing the volume of fibroids in the remaining trials
that did not provide such information, we attempted to
contact the authors of these trials and only the authors of
two trials [16,17] provided detailed information. Volume
of fibroids of 13 trials without clarified parameters was
narratively synthesized.
Methodological quality
All included trials were parallel-group randomised trials,
but only three trials [13,18,19] (7.89%, 3/38) reported
method of sequence generation (using random number
table). No trial described allocation concealment or blind-
ing. Two trials [13,20] (5.26%, 2/38) reported drop-out of
participants, but intention-to-treat analysis was not used.
Figure 1 Flow chart.
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als were all not accessible, we made our judgment by
comparing the outcome measures mentioned in the
method section with the reported outcomes in the re-
sults: 27 trials (71.05%, 27/38) reported all outcome
measures described in the methods were evaluated as
low risk; seven trials [20-26] (18.42%, 7/38) partially re-
ported the outcomes in the results were evaluated as
high risk, and four trials [17,27-29] (10.53%,4/38) were
evaluated as unclear when no description of outcome
measures in the methods. No trial had pre-trial sample
size estimation. All trials were evaluated as high or un-
clear risk of bias (Figure 2; Additional file 2).Figure 2 Methodological quality of included trials (summary of risk oEffect estimation
Volume of uterine fibroids
There were 34 trials that reported the volume of uterine
fibroids. The effect of Guizhi Fuling Formula on volume
of uterine fibroids are summarised in Table 1. We divided
subgroups based on different parameters representing the
volume of fibroids.
Guizhi Fuling Formula versus mifepristone Five trials
in different subgroups reported the volume of uterine fi-
broids. In a three-arm trial [15], increased and common
dosages of Guizhi Fuling capsules were designed to
compare with mifepristone. No significant differencef bias).
Table 1 Effect estimate of Guizhi Fuling Formula for volume of uterine fibroids
Parameters representing the volume of fibroids Study ID MD [95% CI] P value
Guizhi Fuling Formula versus mifepristone
Average volume of maximum fibroids Zhu YJ [30] −1.43 [−3.23, 0.37] 0.12
Total volume of multiple fibroids aGao CR b [14] −3.00 [−16.65, 10.65] 0.67
Average volume of multiple fibroids Xiong DM [31] 0.50 [0.12, 0.88] 0.01
Volume of fibroids without clarified parameters bHu WH a [15] 0.19 [−0.12, 0.50] 0.22
cHu WH b [15] −0.62 [−0.86,-0.38] <0.00001
Guizhi Fuling Formula plus mifepristone versus mifepristone
Average volume of maximum fibroids Chen XJ [32] −0.60 [−1.19, -0.01] 0.05
Gu Y [33] −0.83 [−1.50, -0.16] 0.02
Teng MJ [34] −19.36 [−24.33, -14.39] <0.00001
Wu YF [35] −4.34 [−7.48, -1.20] 0.007
Yang ZQ [36] −0.58 [−1.16, -0.00] 0.05
Yue Li [37] −2.32 [−5.35, 0.71] 0.13
Zhao YF [19] −3.28 [−4.47, -2.09] <0.00001
Zhong GP [38] −6.75 [−9.19, -4.31] <0.00001
Subgroup meta-analysis (random, I2 = 93%) −3.35 [−4.84, -1.87] <0.00001
Total volume of multiple fibroids aGao CR a [14] −15.00 [−28.95,-1.05] 0.04
Lu HJ [39] −22.90 [−35.31,-10.49] 0.0003
Subgroup meta-analysis (fixed, I2 = 0%) −19.41 [−28.68,-10.14] <0.0001
Average volume of multiple fibroids Chen LQ [21] −1.03 [−1.40, -0.66] <0.00001
Gu HH [16] −0.87 [−1.32, -0.42] 0.0001
Xiong DM [24] −1.06 [−1.48, -0.64] <0.00001
Subgroup meta-analysis (fixed, I2 = 0%) −1.00 [−1.23, -0.76] <0.00001
Volume of fibroids without clarified parameters Deng XL [22] −0.68 [−2.38, 1.02] 0.43
Li LJ [40] −2.00 [−16.17, 12.17] 0.78
Luan F [20] −0.68 [−1.95, 0.59] 0.29
Mao CX [41] −0.85 [−1.09, -0.61] <0.00001
Mao XG [23] −7.10 [−10.14, -4.06] <0.00001
Wang JY [42] −5.40 [−8.73, -2.07] 0.001
Wang XR [18] −1.35 [−1.77, -0.93] <0.00001
Wu JH [43] −3.10 [−4.18, -2.02] <0.00001
Ying LJ [25] −1.24 [−2.55, 0.07] 0.06
Zhang LY [26] −1.11 [−2.46, 0.24] 0.11
aGao CR with three arms had two comparisons. bHu WH a: Guizhi Fuling capsules were taken 3# three times daily for 6 months; cHu WH b: Guizhi Fuling capsules
were taken 5# three times daily for 2 months and 3# three times daily for 4 months.
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capsules and mifepristone on reducing volume of fi-
broids (p = 0.22). But when the dosage of Guizhi Fuling
capsules was increased, fibroid volume decreased as
compared with mifepristone (p < 0.00001). One trial
[31] showed mifepristone had better effect in reducing
volume of fibroids (p = 0.01). One trial [27] reported no
significant difference between Guizhi Fuling Formula
and mifepristone in reducing average diameter of fi-
broids (cm) (MD −2.20, 95% CI −4.55 to 0.15, p = 0.07).Guizhi Fuling Formula versus other Chinese patent
medicine Two trials [28,44] reported number of par-
ticipants with shrinkage of fibroids based on different
standards. One trial [28] defined volume reduction ra-
tio of fibroids ≥ 80% as markedly effective (RR 1.37,
95% CI 0.54 to 3.45, p = 0.50), and defined 21% < volume
reduction ratio of fibroids < 80% as effective (RR 0.99,
95% CI 0.75 to 1.29, p = 0.93). Another trial [44] defined
volume reduction ratio of fibroids ≥ 50% as effective
(RR 0.96, 95% CI 0.79 to 1.17, p = 0.69).
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western medicine Twenty eight trials are in this com-
parison, and they applied different parameters to repre-
sent the volume of uterine fibroids.
Eight trials reported average volume of maximum fi-
broids, and the heterogeneity is significant (I2 = 93%, ran-
dom, P < 0.00001) (Additional file 3), which may due to
clinical heterogeneity or low methodological quality.
Pooling results of two trials [14,39] (Additional file 4)
that reported total volume of multiple fibroids and three
trials [16,21,24] (Additional file 5) that reported average
volume of multiple fibroids, favored Guizhi Fuling Formula
plus mifepristone in reducing volume of fibroids.
Ten trials were in the subgroup of volume of fi-
broids without clarified parameters, Of which five tri-
als [18,23,41-43] showed that Guizhi Fuling Formula
plus mifepristone had better effect on reducing volume
of fibroids.
One trial [17] reported the volume change of fibroids
from baseline, favoring Guizhi Fuling Formula plus mife-
pristone in reducing volume of fibroids (MD 6.39, 95% CI
5.93 to 6.85, p < 0.00001). One trial [45] comparing Guizhi
Fuling Formula plus testosterone propionate versus testos-
terone propionate alone showed no significant difference
on reducing fibroid volume (MD −1.45, 95% CI −4.09 to
1.19, p = 0.28). One trial [46] reported average diameter
of fibroids, showing Guizhi Fuling Formula plus mife-
pristone had better effect on reducing diameter of fi-
broids (MD −0.22, 95% CI −0.33 to −0.11, p = 0.0001).
Two trials [47,48] reported number of participants with
shrinkage of fibroids based on different standards. One
of the two trials [47] defined volume reduction ratio of
fibroids ≥ 60% as markedly effective (RR 1.47, 95% CI
1.10 to 1.96, p = 0.009), and defined 20% ≤ volume re-
duction ratio of fibroids < 60% as effective (RR 0.73, 95%
CI 0.41 to 1.29, p = 0.27). The other trial [48] defined
volume reduction ratio of fibroids ≥ 30% as markedly ef-
fective (RR 1.44, 95% CI 1.00 to 2.10, p = 0.05), and de-
fined 10% < volume reduction ratio of fibroids < 30% as
effective (RR 0.88, 95% CI 0.61 to 1.28, p = 0.51).
Improvement of fibroids-related symptoms
Five trials [15,21,24,31,44] reported the number of par-
ticipants whose fibroid-related symptoms were improved
(Table 2). Data of the five trials could not be pooled due
to ambiguous definition of improvement of symptoms.
Guizhi Fuling Formula versus mifepristone Guizhi
Fuling Formula was found in one trial [31] to improve
dysmenorrhea symptoms over mifepristone.
Guizhi Fuling Formula versus other Chinese patent
medicine One trial [44] showed no significant difference
between Guizhi Fuling Formula and another Chinesepatent medicine in number of participants with im-
provement of fibroid-related symptoms.
Guizhi Fuling Formula plus mifepristone versus mife-
pristone One trial [24] favored Guizhi Fuling Formula
plus mifepristone in number of participants with improve-
ment of dysmenorrhea.
Volume of uterus
Twelve trials reported the volume of uterus.
Guizhi Fuling Formula versus mifepristone One trial
[14] reported there was no significant difference between
Guizhi Fuling Formula and mifepristone on reducing vol-
ume of uterus (MD 17.00, 95% CI −9.98 to 43.98, p = 0.22).
Another trial [49] reported total volume of uterus and
fibroids, and found mifepristone was superior to Guizhi
Fuling Formula in reducing total volume of uterus and fi-
broids (MD 112.52, 95% CI 88.52 to 136.52, p < 0.00001).
Guizhi Fuling Formula versus other Chinese patent
medicines One trial [13] reported the average of the sum
of three diameters of uterus, finding no significant differ-
ence between Guizhi Fuling Formula and other Chinese
patent medicines in reducing diameters (MD −0.22, 95%
CI −0.91 to 0.47, p = 0.53).
Guizhi Fuling Formula plus mifepristone versus mife-
pristone Nine trials [14,19,20,22,25,26,34,42,43] reported
uterine volume (Table 3).
Even when random-effect model was applied, heterogen-
eity was too large (I2 = 94%), which may have been due to
clinical heterogeneity or low methodological quality. We
explored the existence of heterogeneity. When we excluded
two trials [14,34] with outliers of larger volume of uterus
before treatment, the pooling data showed Guizhi Fuling
Formula plus mifepristone had better effect on reducing
uterine volume than mifepristone alone (MD −15.45, 95%
CI −19.09 to −11.81, I2 =30%, fixed, p < 0.00001). So we
considered that heterogeneity may have resulted from the
particularity of included participants.
Safety
No trial reported serious adverse events. Twenty-three tri-
als (60.53%, 23/38) did not report information about ad-
verse events. Fifteen trials (39.47%, 15/38) reported
adverse events, including nausea, vomiting, gastrointes-
tinal discomfort, poor appetite, stomachache, distending
pain of the breasts, sensation of bearing down and expan-
sion in the anal region, weakness, sleepiness, hyperhidro-
sis, hectic fever, vaginal bleeding at times other than
menstruation, low libido, dizziness, headache, palpitation,
abdominal pain or abdominal distension, impaired liver
function, and pruritus. Thirteen trials (34.21%, 13/38)
Table 2 Effect estimate of the number of participants with improvement of symptoms
Symptoms Study ID RR [95% CI] P value
Guizhi Fuling Formula versus mifepristone
Heavy menstrual bleeding aHu WH a [15] 1.20 [0.63, 2.29] 0.58
bHu WH b [15] 1.25 [0.67, 2.32] 0.48
Xiong DM [31] 1.09 [0.89, 1.34] 0.42
Prolonged menstrual bleeding Hu WH a [15] 1.05 [0.77, 1.44] 0.76
Hu WH b [15] 1.03 [0.76, 1.40] 0.86
Xiong DM [31] 1.10 [0.92, 1.30] 0.30
Vaginal bleeding at times other than menstruation Hu WH a [15] 1.20 [0.63, 2.29] 0.58
Hu WH b [15] 1.25 [0.67, 2.32] 0.48
Xiong DM [31] 2.00 [0.37, 10.92] 0.42
Distention pain of lower back and abdomen Hu WH a [15] 1.10 [0.79, 1.55] 0.57
Hu WH b [15] 1.18 [0.88, 1.58] 0.27
Xiong DM [31] 1.20 [0.77, 1.87] 0.41
Dysmenorrhea Hu WH a [15] 1.16 [0.77, 1.74] 0.48
Hu WH b [15] 1.21 [0.84, 1.75] 0.30
Xiong DM [31] 2.27 [1.04, 4.97] 0.04
Guizhi Fuling Formula versus other Chinese patent medicine
Prolonged menstrual bleeding Long X [44] 0.91 [0.73, 1.13] 0.38
Heavy menstrual bleeding Long X [44] 0.85 [0.67, 1.10] 0.22
Distention of lower abdomen Long X [44] 0.96 [0.76, 1.21] 0.73
Guizhi Fuling Formula plus mifepristone versus mifepristone
Heavy menstrual bleeding Chen LQ [21] 1.11 [0.94, 1.31] 0.24
Xiong DM [24] 1.13 [0.93, 1.37] 0.22
Prolonged menstrual bleeding Chen LQ [21] 1.05 [0.89, 1.23] 0.56
Xiong DM [24] 1.10 [0.92, 1.30] 0.30
Vaginal bleeding at times other than menstruation Chen LQ [21] 1.60 [0.55, 4.68] 0.39
Xiong DM [24] 1.13 [0.42, 3.00] 0.81
Distention pain of lower back and abdomen Chen LQ [21] 1.60 [0.95, 2.68] 0.08
Xiong DM [24] 1.74 [0.98, 3.09] 0.06
Dysmenorrhea Chen LQ [21] 1.31 [0.92, 1.86] 0.14
Xiong DM [24] 2.35 [1.15, 4.82] 0.02
aHu WH a: Guizhi Fuling capsules were taken 3# three times daily for 6 months; bHu WH b: Guizhi Fuling capsules were taken 5# three times daily for 2 months
and 3# three times daily for 4 months.
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verse events.
Meta-analysis of two trials [27,30] comparing Guizhi
Fuling Formula with mifepristone showed Guizhi Fuling
Formula was potentially safer than mifepristone based on
the incidence of adverse events (RR 0.42, 95% CI 0.24 to
0.75, p = 0.003, I2 = 46%, fixed).
Meta-analysis of 11 trials [17,21,23-25,29,38,41,46,48,50]
comparing Guizhi Fuling Formula plus mifepristone with
mifepristone alone showed Guizhi Fuling Formula plus
mifepristone might experience less adverse events than
mifepristone alone (RR 0.69, 95% CI 0.52 to 0.91, p = 0.01,




Twenty-one trials in our study (three meta-analyses and
eight individual trials) showed that Guizhi Fuling Formula
plus mifepristone may be more effective than mifepristone
alone in reducing the volume of fibroids. Nine trials (one
meta-analysis) showed that Guizhi Fuling Formula plus
mifepristone may be more effective than mifepristone
alone in reducing the volume of the uterus. The two find-
ings were consistent with the Cochrane review [11], but
Table 3 Effect estimate of Guizhi Fuling Formula for
volume of uterus (cm3)a
Study ID MD [95% CI] P value
Deng XL [22] −15.80 [−29.29, -2.31] 0.02
Gao CR [14] −100.00 [−125.53, -74.47] <0.00001
Luan F [20] −15.80 [−28.54, -3.06] 0.02
Teng MJ [34] −74.75 [−86.45, -63.05] <0.00001
Wang JY [42] −11.00 [−16.04, -5.96] <0.0001
Wu JH [43] −23.50 [−34.26, -12.74] <0.0001
Ying LJ [25] −28.80 [−47.82, -9.78] 0.003
Zhang LY [26] −18.38 [−30.15, -6.61] 0.002
Zhao YF [19] −23.16 [−36.41, -9.91] 0.0006
Meta-Analysis (random,I2 = 94%) −33.14 [−48.92, -17.36] <0.0001
aComparison for this outcome is Guizhi Fuling Formula plus mifepristone
versus mifepristone.
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of the number of trials between the Cochrane review and
our review could be accounted for by the newer search,
different search strategies, and inclusion/exclusion criteria.
We also found that one trial [31] favored Guizhi Fuling
Formula over mifepristone alone with regard to the num-
ber of participants with improvement of dysmenorrhea.
Another trial [24] found Guizhi Fuling Formula plus mife-
pristone had better effect than mifepristone on number of
participants with improvement of dysmenorrhea. Two tri-
als (one meta-analysis) [27,30] showed Guizhi Fuling For-
mula was potentially safer than mifepristone, and 11 trials
(one meta-analysis) showed Guizhi Fuling Formula plus
mifepristone resulted in fewer adverse events than mife-
pristone alone.
Strengths and limitations
There are several strengths in this study. This is a system-
atic review and meta-analysis on an important topic of
women health. The search for eligible trials was com-
prehensive and most of the included RCTs identified in
Chinese databases were not found in English databases.
We had a standard protocol registration in PROSPERO, an
international prospective register of systematic reviews, and
published the protocol. Moreover, we rigorously assessed
the methodological quality of included trials.
Our study also has several limitations. The methodo-
logical quality of the included trials was generally poor.
The majority of trials did not report randomization proce-
dures and all trials lacked information on blinding. Add-
itionally, intention-to-treat analysis and pre-trial sample
size estimate were not applied. We failed to perform a fun-
nel plot analysis due to insufficient number of included
trials in meta-analysis, so there may be potential publica-
tion bias. Two meta-analyses were limited in performance
due to very large unexplained heterogeneity. Though we
endeavored to contact trial authors to clarify the missinginformation, responses were not satisfactory. We tried to
compare Guizhi Fuling Formula with other Chinese patent
medicines, but failed to draw any conclusions due to the
limited number of such trials.
Interpretation
The mechanism of Guizhi Fuling Formula to shrink or
eliminate fibroids and improve clinical manifestations
might be as follows: Guizhi Fuling Formula inhibits tumor
growth, angiopoiesis [51] and inflammation [52]. In terms
of Chinese medicine actions, the formula invigorates
blood, dissolves stasis, and resolves masses [9].
Implications for further study
Most of included trials lacked detailed information on
methodology, since the reporting of most RCTs published
in the Chinese literature did not follow the CONSORT
statement. Furthermore, the low number of telephone or
e-mail responses of original authors did not provide some
of the missing information we needed. To improve meth-
odological quality of clinical trials, we suggest the follow-
ing issues should be addressed: randomisation methods
need to be described clearly and reported fully; double
blinding should be carried out with the use of adequate
placebo, if possible, although blinding of participants and
practitioners may be difficult for different traditional
Chinese preparations, at the very least every attempt should
be made to blind outcome assessors and statisticians; with-
drawal/dropout during the trial and use of intention-to-
treat analysis should be clearly described; pre-trial sample
size should be estimated; the protocol should be registered
and reported as a link in the article.
For outcome measures, fibroid or uterine volume and
clinically relevant outcomes are important for clinical re-
search on uterine fibroids. Volume can be determined by
measuring length, height, and width, and calculated with
the equation for a prolate ellipse using π/6(0.523) ×
length × width × height [53]. Although there is no standard
in reporting fibroid volume, the volume of the maximum
fibroid could be a good choice as it is easier to carry out
and is more accurate. Clinically relevant outcomes, such
as fibroid-related symptoms, quality of life, should be ad-
dressed and measured using validated instruments, such
as a pictorial blood-loss assessment chart, Short-Form
McGill Pain Questionnaire or visual-analogue scale for
pain, and the uterine fibroid symptoms quality of life
(UFS-QOL) questionnaire. In addition, composite out-
comes are not preferred and we recommend each out-
come should be reported individually with clear definition
or judgment. Finally, future trials should pay more atten-
tion to adverse events, especially long-term safety of the
therapy being investigated. Adverse events should be re-
corded and reported completely, using international
standard medical terms.
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The findings of the current trials suggest that Guizhi
Fuling Formula plus mifepristone may be more effective
than mifepristone alone for the treatment of uterine fi-
broids in reducing the volume of fibroids or uterus.
However, due to poor methodological quality, we could
not draw confirmative conclusions on the beneficial
effect of Guizhi Fuling Formula plus mifepristone for uter-
ine fibroids. We recommend that further well-designed
clinical trials with large sample sizes be undertaken.
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